Aminorex

Summary

Aminorex (CHEMBL106258) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 162.19 Da · C9H10N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL106258
Name	Aminorex
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	16630
Molecular formula	C9H10N2O
Molecular weight	162.19
InChIKey	SYAKTDIEAPMBAL-UHFFFAOYSA-N

SMILES: C1C(OC(=N1)N)C2=CC=CC=C2

IUPAC name: 5-phenyl-4,5-dihydro-1,3-oxazol-2-amine

Also known as: Aminorex, Aminoxaphen, Apiquel, MCN-742, NSC-66952, AMINOREX

Patent coverage: 582 distinct patent families (2,248 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).